BE vs RTX

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Despite explosive revenue growth of 57.1% and strong recent earnings surprises, the company trades at extreme valuations (P/E of 2069, P/B of 52.44) far above sector averages, while profitability remains thin (ROE: 2.93%, net margin: 0.84%). Aggressive insider selling worth $20.85M over the past six months and a bearish technical trend (10/100) further signal caution. Although analysts recommend a 'buy', the stock appears significantly overvalued relative to both defensive (Graham Number: $2.09) and growth-based intrinsic value ($0.49), suggesting elevated downside risk.

RTX exhibits stable financial health with a Piotroski F-Score of 5/9, yet it is trading at a severe premium compared to its Graham Number ($73.73) and Intrinsic Value ($96.67). While the company boasts an exceptional track record of earnings beats over 25 quarters and solid revenue growth, the valuation is stretched with a PEG ratio of 2.75. This fundamental overvaluation is compounded by bearish insider sentiment and a weak technical trend, suggesting that while the business is strong, the stock price is currently decoupled from its deterministic value.